David F. McDermott

机构：Beth Israel Deaconess Medical Center · ORCID：0000-0002-2675-5095

发表论文 1100 篇 · 总被引 90887 次 · h-index 110

代表论文

Is it time to reassess standard toxicity and patient reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)? (2026 · Annals of Oncology)
Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial (2026)
Supplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial (2026)
Supplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial (2026)
Supplementary Table S4 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial (2026)
Supplementary Table S7 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial (2026)